úÁÑ×ÌÅÎÉÅ Ï ËÏÎÆÌÉËÔÅ ÉÎÔÅÒÅÓÏ× ×ÙÐÁÌÏ ÉÚ ÐÅÒÅ×ÏÄÁ:
Fidaxomicin Beats Vancomycin for C difficile in Cancer
Becky McCall
*This phase 3 trial was funded by Optimer Pharmaceuticals Inc. Dr. Cornely
reports receiving funding from the Federal Ministry of Research and
Education (BMBF 01KN1106, 01KN0706, 01GH1001E, 01EZ0931), the German
Research Foundation, the German Center for Infectious Disease Research, the
German José Carreras Leukaemia Foundation, and the European Organization
for Research and Treatment of Cancer; and receiving research grants or
being a speaker for Actelion, Astellas, Basilea, Bayer, F2G, Gilead,
Menarini, MSD, Miltenyi, Novartis, Optimer, Pfizer, Quintiles, Viropharma.
Dr. Lechner has disclosed no relevant financial relationships. Dr. Lodes
reports receiving a travel grant from Astellas.*
22nd European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID): Poster 2289 and abstract O670. Presented April 3, 2012.
Medscape Medical News © 2012 WebMD, LLC
Send comments and news tips to news@medscape.net.
Optimer Pharmaceuticals Inc. Dr.
Cornely reports receiving funding from the Federal Ministry of Research and
Education (BMBF 01KN1106, 01KN0706, 01GH1001E, 01EZ0931), the German
Research Foundation, the German Center for Infectious Disease Research, the
German José Carreras Leukaemia Foundation, and the European Organization
for Research and Treatment of Cancer; and receiving research grants or
being a speaker for Actelion, Astellas, Basilea, Bayer, F2G, Gilead,
Menarini, MSD, Miltenyi, Novartis, Optimer, Pfizer, Quintiles, Viropharma.
Dr. Lechner has disclosed no relevant financial relationships. Dr. Lodes
reports receiving a travel grant from Astellas.